The State of Mesothelioma in America
2026 Annual Report

Executive Summary

This report synthesizes the most current data available on mesothelioma incidence, mortality, treatment advances, compensation landscape, legislative changes, and state-level impact. It is intended as a reference resource for patients, families, researchers, journalists, and legal professionals.

Incidence & Mortality: The Numbers in 2026

Mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Because of its 20–50 year latency period, the full toll of mid-20th-century industrial asbestos use is still being felt today.

Trends: Slow Decline After Decades of Plateau

Mesothelioma incidence in the United States peaked in the late 1990s and has since entered a period of gradual decline. Age-adjusted incidence rates fell from approximately 1.3 per 100,000 in 1999 to around 1.1 per 100,000 in the most recent reporting period — a modest but meaningful improvement. Epidemiologists attribute this trend to the phased reduction in occupational asbestos exposure that began with OSHA regulation in the 1970s, now manifesting in mortality data 20–40 years later.

However, the plateau has not ended. Because chrysotile asbestos continued to be imported and used in industrial applications through the early 2000s — and because global asbestos production remains high in countries like Russia, Kazakhstan, and Brazil — public health researchers warn against projecting rapid declines. The latency period means people exposed in the 1980s and 1990s are only now entering peak diagnosis years.

Survival Rates: Improving but Still Poor

The 5-year relative survival rate for mesothelioma has improved over the past decade — from approximately 9% in 2010 to 12% in the most recent NCI SEER data — driven largely by earlier detection, improved surgical techniques, and the introduction of immunotherapy. However, mesothelioma remains one of the most lethal cancers in the American registry. Stage at diagnosis remains the strongest predictor of survival:

Top 10 States by Mesothelioma Deaths (1999–2019)

Mesothelioma deaths are not uniformly distributed across the country. States with heavy concentrations of shipyards, steel mills, oil refineries, and manufacturing plants have consistently recorded the highest total deaths and age-adjusted mortality rates. The following table shows the ten states with the highest total mesothelioma deaths in CDC WONDER data covering 1999–2019:

Treatment Advances: 2025–2026

Mesothelioma treatment has undergone more meaningful change in the past three years than in the prior decade. Immunotherapy combinations have reached standard-of-care status, device-based therapies have entered clinical practice, and precision medicine approaches are entering the pipeline.

Trust Fund & Compensation Landscape: 2026 Update

The asbestos litigation system has produced the largest mass tort compensation framework in American legal history. For most mesothelioma patients and families, multiple sources of compensation are available simultaneously — trust fund claims, litigation against solvent defendants, and VA benefits for veterans.

How Asbestos Trust Funds Work

When a major asbestos manufacturer filed for bankruptcy protection — as dozens did beginning with Johns-Manville in 1982 — courts required the company to establish a trust fund specifically to compensate future asbestos claimants. Each trust operates under a Trust Distribution Procedure (TDP) document that sets scheduled values for different diseases, payment percentages (the share of scheduled value actually paid), and documentation requirements.

Because asbestos-containing products were manufactured and sold by hundreds of companies over many decades, most mesothelioma patients have exposure histories that implicate multiple manufacturers — meaning multiple trust claims can often be filed simultaneously. An experienced mesothelioma attorney conducts a thorough work-history review to identify all potentially applicable trusts.

Notable Verdicts and Settlements: 2025

Courtroom verdicts continue to set precedents and demonstrate the magnitude of individual case values:

Trust Fund Payment Rate Changes

Several major trusts adjusted their payment percentages during 2024–2025. Payment percentages reflect the trust's estimate of its long-term solvency — the share of the full scheduled disease value the trust pays out today to preserve funds for future claimants. As trusts mature and actuarial projections are updated, these percentages can change. Notable 2025 adjustments included the Owens Corning/Fibreboard Trust (reduced from 4.5% to 4.1%), the Armstrong World Industries Trust (stable at 5.25%), and the W.R. Grace Trust (adjusted from 25% to 22%). Claimants should always verify current rates with a qualified attorney, as percentages are updated periodically and the difference in actual payout can be meaningful even on small percentage changes applied to large scheduled values.

Legislative & Regulatory Updates

The regulatory environment surrounding asbestos shifted significantly in 2024, with the EPA finalizing rules that could mark a historic turning point — even as the legislation faces ongoing legal and political headwinds.

EPA Comprehensive Asbestos Rule (TSCA Section 6) — 2024

On March 18, 2024, the Environmental Protection Agency finalized a rule under Section 6 of the Toxic Substances Control Act (TSCA) prohibiting the ongoing use of chrysotile asbestos in the United States — the only commercially imported form of asbestos still in use in American manufacturing, primarily in chlor-alkali plants that use asbestos diaphragms to produce chlorine and caustic soda. The rule phases out this remaining use over a two-year period beginning in 2026.

The final rule does not address legacy asbestos already installed in buildings, pipes, insulation, and other materials across the country — a significant limitation, as in-place asbestos in older structures continues to be a source of exposure during renovation, demolition, and repair work. Environmental and public health advocates have called for a more comprehensive approach to legacy asbestos management.

FAIR Act — Congressional Status

The Furthering Asbestos Claim Transparency (FACT) Act has been reintroduced in successive Congresses. Proponents argue it would curb fraudulent double-billing across trust fund and litigation systems; opponents — including patient advocacy organizations — argue it would expose claimants' sensitive medical and financial information and erect procedural barriers that disproportionately harm legitimate claimants. As of March 2026, the Act has not passed the Senate.

State-Level Asbestos Legislation

Several states have enacted or are advancing their own asbestos-related legislation in the absence of federal action:

• California: Continues to enforce the most aggressive asbestos abatement and worker protection standards in the nation, with CalOSHA standards that exceed federal OSHA requirements.
• New York: Maintains robust asbestos litigation infrastructure in New York City courts, with the New York City Asbestos Litigation (NYCAL) docket among the most active in the country.
• Texas: The Multidistrict Asbestos Litigation (MDL) in Beaumont continues to process thousands of claims annually under specialized procedural rules developed to handle high-volume asbestos dockets.
• Illinois: Madison County courts have historically been a forum of choice for asbestos plaintiffs, due to plaintiff-friendly procedural rules and jury composition trends.

Veterans & Military: Still Disproportionately Affected

Military veterans account for approximately one in three mesothelioma patients in the United States — a staggering disproportion relative to their share of the general population. This reflects the military's extensive use of asbestos throughout the 20th century.

Why Veterans Are at Elevated Risk

The U.S. military used asbestos extensively in ships, aircraft, vehicles, and buildings from roughly 1930 through the late 1970s. Asbestos was prized for its fire-resistance, thermal insulation properties, and durability in the harsh environments of military service. Navy veterans who served aboard ships are at the highest risk, as vessels were insulated throughout with asbestos-containing materials — boiler rooms, engine rooms, pipe coverings, and sleep quarters. The enclosed, poorly ventilated nature of ships meant that fiber concentrations below deck could be extremely high.

VA Benefits and Claims Processing

Veterans diagnosed with mesothelioma are presumptively eligible for VA disability compensation — the VA recognizes mesothelioma as service-connected when a veteran served in a branch that used asbestos, without requiring them to prove the specific fiber that caused their cancer. As of 2025, the VA has implemented process improvements under the PACT Act framework that have reduced average processing times for mesothelioma disability claims from 125 days to approximately 87 days. Monthly compensation at 100% disability rating is approximately $3,621 for a single veteran (2025 rates), with additional allowances for dependents and the need for regular aid and attendance.

State-by-State Mesothelioma Data — All 50 States

The following table presents mesothelioma mortality data for all 50 U.S. states, drawn from the CDC WONDER Mortality Database (1999–2019) and NCI SEER state-level data. States are sorted by total deaths, highest to lowest.

PI = Personal Injury statute of limitations; WD = Wrongful Death statute. Clock typically begins at date of diagnosis, not exposure. Always verify current statutes with a licensed attorney in the relevant state.

Looking Ahead: Outlook for 2027 and Beyond

The mesothelioma landscape in 2026 is one of cautious optimism — real treatment advances, a strengthening regulatory environment, and improved compensation access — set against the sobering reality that the disease will continue claiming thousands of American lives annually for years to come.

Emerging Treatment Pipeline

The clinical trial pipeline for mesothelioma is more robust than at any prior point. Key developments to watch in 2026–2027:

• Antibody-drug conjugates (ADCs) targeting mesothelin are in Phase II trials. Early data from anetumab ravtansine and other mesothelin-directed ADCs show meaningful tumor responses in pretreated patients.
• Bispecific antibodies simultaneously targeting mesothelin and T cell activating receptors (CD3) are entering first-in-human studies at leading academic centers.
• PARP inhibitors are being studied in BAP1-mutated mesothelioma — a genetically defined subset where preclinical data suggests synthetic lethality may apply similarly to BRCA-mutated breast and ovarian cancers.
• Oncolytic viruses (engineered viruses that selectively replicate in tumor cells) are in early trials for pleural mesothelioma, with direct intrapleural delivery being explored to overcome systemic delivery challenges.
• Second-generation immunotherapy combinations — adding anti-TIGIT, anti-LAG-3, or anti-TIM-3 agents to the established nivolumab/ipilimumab backbone — are under investigation to improve response depth and duration.

Regulatory Outlook

The EPA's 2024 TSCA rule represents genuine progress, but the U.S. remains one of the few developed nations without a comprehensive asbestos ban. Canada, Australia, the European Union, and 65 other countries have enacted full bans. The focus for U.S. regulators in 2026–2027 will be on: (1) enforcing and defending the chrysotile rule against ongoing legal challenges from the chlor-alkali industry; (2) evaluating whether legacy asbestos in existing structures requires enhanced federal management protocols; and (3) monitoring asbestos content in consumer products, where contamination events (notably talc-contaminated cosmetics) continue to create new exposure pathways.

The Latency Pipeline Problem

Perhaps the most important and underappreciated dynamic in the mesothelioma landscape is what epidemiologists call the "latency pipeline" — the population of individuals already exposed to asbestos who have not yet been diagnosed. Given a 20–50 year latency period and the fact that asbestos use continued in many applications through the 1990s and early 2000s, a meaningful number of current workers and tradespeople are carrying future diagnoses. This argues for continued investment in early detection research — including blood-based biomarkers (mesothelin, fibulin-3, high-mobility group box 1 protein) and low-dose CT surveillance protocols — even as the regulatory focus shifts to preventing new exposures.